ArticleNeuromolecular medicine2015
miR26a modulates Th17/T reg balance in the EAE model of multiple sclerosis by targeting IL6.
Article in Neuromolecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 73 citations in OpenAlex.
- miR-451a and IL18 can differentiate familial Mediterranean fever patients in attack and remission periods: a prospective cross-sectional study.Clinical rheumatology · 2025Article
- Interpreting the Function of the IL-23/IL-17 Axis through Bioinformatics.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Unraveling the Epigenetic Landscape: Insights into Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis.Brain sciences · 2024Review
- Curcumin chitosan microspheres regulate Th17/Treg balance via IGF2BP1- mediated m6A modification of LRP5 in ulcerative colitis.Iranian journal of basic medical sciences · 2024Article
- Exploring immune related gene signatures and mechanisms linking non alcoholic fatty liver disease to atrial fibrillation through transcriptome data analysis.Scientific reports · 2023Article
- Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.Molecular therapy oncolytics · 2023Review
- The role of miRNAs in T helper cell development, activation, fate decisions and tumor immunity.Frontiers in immunology · 2023Review
- Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis.EBioMedicine · 2022Article
- MicroRNAs as Modulators of the Immune Response in T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2022Review
- LNCRNA XIST Inhibits miR-377-3p to Hinder Th17 Cell Differentiation through Upregulating ETS1.Computational intelligence and neuroscience · 2022Article
- MicroRNAs as T Lymphocyte Regulators in Multiple Sclerosis.Frontiers in molecular neuroscience · 2022Review
- Extracellular Vesicles From Kidney Allografts Express miR-218-5p and Alter Th17/Treg Ratios.Frontiers in immunology · 2022Article
- Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs.International immunopharmacology · 2021Review
- Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.Non-coding RNA research · 2021Article
- Bushen Yijing Decoction (BSYJ) exerts an anti-systemic sclerosis effect via regulating MicroRNA-26a /FLI1 axis.Bioengineered · 2021Article
- miRNA-Dependent CD4Multiple sclerosis international · 2021Review
- A Two-Step Process of Effector Programming Governs CD4Cell reports · 2020Article
- Noncoding RNAs in inflammation and colorectal cancer.RNA biology · 2020Article
- MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis.Neural regeneration research · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of different microRNAs (miRNAs) have been implicated in various autoimmune diseases, including multiple sclerosis (MS). T helper (Th)17 and regulatory T cells (Tregs) have likewise been implicated as key players in MS, and a functional imbalance of these cell types is increasingly recognized as a key etiological factor in the disease. Although specific panels of transcription factors and cytokines are known to regulate the Th17/Treg balance, the role of noncoding RNAs remains poorly understood. The inflammatory cytokine, interleukin (IL)6, appears to play a critical role in both the development of the Th17 response and the inhibition of Treg functions. In this research, an IL6-associated miRNA, miR26a, was identified, and its normally downregulated expression was shown to be highly correlated with disease severity in patients suffering from MS as well as in C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE; a well-established animal model of human MS). Using the EAE model system, in vivo silencing of miR26a was found to result in increased expression of Th17-related cytokines and increased severity of EAE, while overexpression of miR26a was found to result in reduced expression of Th17-related cytokines and a milder form of EAE. By contrast, Treg cell-specific transcription factor, Foxp3, was found to be positively correlated with miR26a expression. Finally, miR26a was found to downregulate Th17 and to upregulate Treg cell function through its targeting of IL6. Taken together, our data indicate an important role for miR26a in maintaining the Th17 and Treg cell balance in MS that involves repression of IL6 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.